Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Merck & Co (NY: MRK )

123.06 -2.83 (-2.25%)
Streaming Delayed Price Updated: 1:16 PM EDT, Jul 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
87 88 Next >
Benzinga's Top Ratings Upgrades, Downgrades For March 6, 2023
Via Benzinga
US FDA Approves Intramuscular Administration for Merck’s MMRV Family of Vaccines: M-M-RII (Measles, Mumps, and Rubella Virus Vaccine Live), VARIVAX (Varicella Virus Vaccine Live), and ProQuad (Measles, Mumps, Rubella and Varicella Virus Vaccine Live)
From Merck & Co., Inc.
Via Business Wire
Secrets Of Great Long-Term Stock Investors
What can the rest of us learn from Warren Buffett's long-term stock buys? Here are 5 stock ideas for long-term investors. 
Via Talk Markets
Merck Discontinues Two Keytruda Combo Therapy Trials In Prostate & Lung Cancer Settings
Via Benzinga
Here's How Much $1000 Invested In Merck & Co 5 Years Ago Would Be Worth Today
Via Benzinga
US Senators Warren, Sanders Urge 'Close Scrutiny' On Merck's Keytruda-Related Patents
Via Benzinga
Week In Review: Abbisko Out-Licenses Rights To Precision NSCLC Medicine For $188 Million
Abbisko Therapeutics out-licensed Greater China rights to a pre-clinical EGFR-TKI candidate for NSCLC to Allist Pharma in a $188 million deal. Also, Chipscreen Bio acquired greater China rights to a... 
Via Talk Markets
Merck and AstraZeneca Provide Update on US Regulatory Review of LYNPARZA® (olaparib) for Use in Combination With Abiraterone and Prednisone or Prednisolone for the Treatment of Metastatic Castration-Resistant Prostate Cancer
From Merck & Co., Inc.
Via Business Wire
After Shelving Two Keytruda Trials, Merck Touts Encouraging Data From Keytuda Regime Study In Lung Cancer Patients
Via Benzinga
Merck Announces Phase 3 KEYNOTE-671 Trial Met Primary Endpoint of Event-Free Survival (EFS) in Patients With Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer
From Merck & Co., Inc.
Via Business Wire
European Authority Recommends Against Approval For Merck-Ridgeback Biotherapeutics' COVID-19 Pill
Via Benzinga
Expert Ratings for Merck & Co
Via Benzinga
Why Compugen Shares Are Up Today
The company released its fourth-quarter and full-year results after the bell Monday. 
Via The Motley Fool
Is Amazon a Blue Chip Stock?
Is Amazon a blue chip stock or does it fit into a different category? Learn more about Amazon.com Inc. and how to categorize it with MarketBeat. 
Via MarketBeat
What is the Best Dividend ETF?
Dividend ETFs may take a lot of the hassle out of picking stocks, and this one fund has even manged to beat the market over the last decade. 
Via MarketBeat
Topics ETFs Stocks
Exposures US Equities
Merck Provides Update on Phase 3 Trials KEYNOTE-641 and KEYNOTE-789
From Merck & Co., Inc.
Via Business Wire
Analyst Cautions Investors On Overreacting To 'Early-Stage' Pfizer/Seagen Discussions
Via Benzinga
'Here We Go Again': Seagen Soars As Pfizer Reportedly Mulls A Takeover
The potential deal follows rumors last year that Merck could buy Seagen. 
Via Investor's Business Daily
Seagen Stock Soars On Pfizer Takeover Talks: What's Going On?
Seagen Inc (NASDAQ: SGEN) shares are trading higher Monday following reports indicating pharmaceutical giant Pfizer Inc (NYSE: 
Via Benzinga
Pfizer In Early Talks To Buy Cancer-Focused Seagen: WSJ
Via Benzinga
Buy/Sell: Wall Street's Top 10 Stock Calls This Week - Saturday, Feb. 25
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street’s best analysts during the week of Feb. 20-24. 
Via Talk Markets
The Next Generation Of Cancer Vaccines Are Coming; What That Means For Moderna And Other Biotech Stocks
Startling cancer vaccine results from Moderna may point to the next big thing in biotech. 
Via Investor's Business Daily
Merck and Ridgeback Provide Update on EU Marketing Authorization Application for LAGEVRIO™ (Molnupiravir)
From Merck & Co., Inc.
Via Business Wire
Don't Get Panicked Into Selling Off Merck Shares
The current drop in 2023 sales likely won't matter in the long term. 
Via The Motley Fool
Infinity Pharmaceuticals Announce Merger Agreement With MEI Pharma, Share Plunge
Via Benzinga
Moderna Pops After FDA Grants Its Cancer Vaccine A Breakthrough Designation
The companies could see a speedier review process. 
Via Investor's Business Daily
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA(R) (pembrolizumab), was Granted Breakthrough Therapy Designation by the FDA for Adjuvant Treatment of Patients With High-Risk
Via ACCESSWIRE
Benzinga's Top Ratings Upgrades, Downgrades For February 22, 2023
Via Benzinga
This Recession-Proof Company Has a Best-in-Class Dividend
Pfizer's highly attractive valuation, rock-solid dividend program, and enormous yield put it at the top of its big pharma peer group. 
Via The Motley Fool
Merck Opens Enrollment in New Phase 3 Clinical Trials with Investigational Once-Daily Islatravir in Combination with Doravirine for Treatment of HIV-1 Infection
From Merck & Co., Inc.
Via Business Wire
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
87 88 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.